On Tuesday, GSK unveiled new clinical data showing that its Shingrix shingles vaccine remains effective for more than ten years in patients aged over 50.

According to the follow-up results of a Phase III study, the efficacy of its product reached 79.7% in this population between six and 11 years after vaccination.

This rate even rose to 82% in people over 50 years of age after 11 years of vaccination.

In people over 70, efficacy was 73.1% between six and 11 years following vaccination.

According to estimates, 30% of the population will one day suffer from shingles, a disease caused by the varicella virus, a proportion that rises to almost 50% in people living to 85 years of age.

Copyright (c) 2024 CercleFinance.com. All rights reserved.